You are using an outdated browser. Please upgrade your browser to improve your experience and security.

Transcript

John: When I got diagnosed with AML ah nobody in my family had it.

John: I was told it was pretty rare and fast-moving.

Cherie: It was daunting, it was enriching.

Cherie: We learned a lot, and in many ways we became closer.

John: Going in there I knew I was on a clinical trial.

Cherie: We were just so blessed to be there at the right time at the right place and have a spot that they wanted an old man to try.

John: Being on a clinical trial was… well it saved me, really.

John: Being in the hospital you know you’re going to have time other than being interrupted every four hours for a lot of things and I decided I’m going to keep a log of what happens. You-you know you’re going to have time in between and so I did a lot of walking and they told me when I checked into that hospital that 11 times around the out- the per-perimeter was a mile. So I set goals, I’m gonna do my exercise.

John: There were a few days where I had trouble getting up and ah I did walk around but I didn’t record… I mentioned that I didn’t do any laps. What I call laps are when I was really moving… and ah I did get up and walk around very slowly and… those days I didn’t do much. But I had to try and do something.

John: My advice for somebody going through this is have the support, have a positive positive attitude, keep in shape, the best shape you can be.

John: Ah We - we look at it like it’s a new day every day.

INDICATION

VYXEOS (daunorubicin and cytarabine) liposome for injection 44 mg/100 mg is indicated for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

IMPORTANT SAFETY INFORMATION

INDICATION

VYXEOS (daunorubicin and cytarabine) liposome for injection 44 mg/100 mg is indicated for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

Important Safety Information

WARNING: DO NOT INTERCHANGE WITH OTHER DAUNORUBICIN AND/OR CYTARABINE-CONTAINING PRODUCTS

VYXEOS has different dosage recommendations than daunorubicin hydrochloride injection, cytarabine injection, daunorubicin citrate liposome injection, and cytarabine liposome injection. Verify drug name and dose prior to preparation and administration to avoid dosing errors.